Profile data is unavailable for this security.
About the company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-7.61m
- Incorporated2014
- Employees10.00
- LocationMonopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
- Phone+1 (847) 388-0349
- Fax+1 (302) 655-5049
- Websitehttps://www.monopartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd - ADR | 0.00 | -24.22m | 11.51m | 20.00 | -- | 0.0339 | -- | -- | -42.37 | -42.37 | 0.00 | 23.93 | 0.00 | -- | -- | 0.00 | -74.28 | -- | -90.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| ABVC Biopharma Inc | 152.43k | -10.52m | 11.62m | 16.00 | -- | 1.04 | -- | 76.21 | -2.52 | -2.52 | 0.0352 | 1.06 | 0.0127 | -- | 0.3514 | 9,526.88 | -90.65 | -103.38 | -171.60 | -231.54 | -98.15 | 76.25 | -7,157.57 | -2,019.89 | -- | -3.28 | 0.153 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Eterna Therapeutics Inc | 68.00k | -21.68m | 11.69m | 8.00 | -- | 5.24 | -- | 171.86 | -4.08 | -4.08 | 0.0128 | 0.4128 | 0.0019 | -- | 0.0988 | 8,500.00 | -60.69 | -169.05 | -75.78 | -223.00 | -173.53 | -- | -31,864.71 | -682.61 | -- | -33.19 | 0.7813 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| ELEVAI Labs Inc | 1.71m | -4.30m | 11.83m | 18.00 | -- | 3.09 | -- | 6.91 | -0.2482 | -0.2482 | 0.0988 | 0.2208 | -- | -- | -- | 95,143.89 | -- | -- | -- | -- | 66.25 | -- | -251.17 | -- | 3.41 | -41.16 | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Avalo Therapeutics Inc | 1.93m | -31.54m | 11.88m | 19.00 | -- | 1.26 | -- | 6.17 | -381.36 | -381.36 | 6.94 | 9.11 | 0.0708 | 128.50 | 1.87 | 101,315.80 | -116.06 | -99.64 | -228.35 | -154.42 | 33.25 | 84.69 | -1,638.65 | -613.58 | 1.82 | -5.67 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Pioneer Green Farms Inc | 9.29k | -403.37k | 11.94m | 6.00 | -- | -- | -- | 1,285.15 | -0.0172 | -0.0172 | 0.0004 | -0.026 | 0.0154 | 0.3035 | -- | 1,548.33 | -66.94 | -- | -- | -- | 41.44 | -- | -4,341.98 | -- | 0.0106 | -30.89 | -- | -- | -- | -- | 35.41 | -- | -- | -- |
| Energy Finders Inc | 4.06m | -2.92m | 12.30m | 46.00 | -- | -- | -- | 3.03 | -0.272 | -0.272 | 1.52 | 3.04 | -- | -- | -- | 88,304.35 | -- | -- | -- | -- | 27.45 | -- | -71.79 | -- | 0.6706 | -12.57 | 0.564 | -- | -- | -- | -- | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -7.61m | 12.41m | 10.00 | -- | -- | -- | -- | -0.5289 | -0.5289 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Endexx Corp | 4.64m | 6.93m | 12.61m | -- | 1.87 | -- | 2.13 | 2.72 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 12.74m | 12.00 | -- | 0.6121 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -10.01m | 12.96m | 9.00 | -- | -- | -- | -- | -2.04 | -2.04 | 0.00 | -0.0346 | 0.00 | -- | -- | 0.00 | -110.06 | -149.95 | -1,281.64 | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.62m | 12.99m | 85.00 | -- | 0.4741 | -- | -- | -3.01 | -3.01 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -44.86 | -58.80 | -48.21 | -66.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.08 | -- | 16.04 | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -21.27m | 13.21m | 5.00 | -- | 3.00 | -- | -- | -0.8922 | -0.8922 | 0.00 | 0.1221 | 0.00 | -- | -- | 0.00 | -266.05 | -36.90 | -392.90 | -37.81 | -- | -- | -- | -- | -- | -- | 0.2068 | -- | -- | -- | 43.40 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 13.25m | 22.00 | -- | 2.39 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Notable Labs Ltd | 310.00k | -11.26m | 13.35m | 16.00 | -- | 0.8831 | -- | 43.05 | -3.08 | -3.08 | 0.0939 | 1.68 | 0.0126 | -- | -- | 19,375.00 | -45.79 | -52.02 | -56.70 | -62.09 | 36.45 | 60.19 | -3,633.55 | -3,636.93 | -- | -- | 0.0221 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
Data as of May 10 2024. Currency figures normalised to Monopar Therapeutics Inc's reporting currency: US Dollar USD
1.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 48.09k | 0.32% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 45.17k | 0.30% |
| Geode Capital Management LLCas of 31 Dec 2023 | 41.20k | 0.28% |
| Millennium Management LLCas of 31 Dec 2023 | 29.34k | 0.20% |
| Gerber LLCas of 31 Mar 2024 | 28.01k | 0.19% |
| Virtu Americas LLCas of 31 Dec 2023 | 27.17k | 0.18% |
| Two Sigma Investments LPas of 31 Dec 2023 | 14.30k | 0.10% |
| UBS Securities LLCas of 31 Dec 2023 | 11.90k | 0.08% |
| G1 Execution Services LLCas of 31 Dec 2023 | 10.99k | 0.07% |
| Rappaport Reiches Capital Management LLCas of 31 Mar 2024 | 10.70k | 0.07% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
